Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-UteCIN adjuvant chemotherapy in high-risk localized resected uterine leiomyosarcoma
2023-506350-21-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Jan 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in uterine leiomyosarcoma (uLMS) comparing Adjuvant doxorubicin + trabectedin with Observation / no adjuvant chemotherapy (2 arms). Primary endpoint: Recurrence-free survival. Planned start Jan 2025; status: authorised.
02
Drugs
trabectedindoxorubicin
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on 2023-506350-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506350-21-00.